ReviewBiomedicines2024
Flavonoids as CYP3A4 Inhibitors In Vitro.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 24 citations in OpenAlex.
- Trial
- Allosteric Interactions of Flavonoids with ACE2 and Potential Implications for COVID-19: Computational Insights, Metabolic and Mitochondrial Effects of Rutin in A549 Cells.Cell biochemistry and biophysics · 2026Article
- Epigenetic Modulation by Luteolin, Quercetin and Apigenin in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Mechanisms and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- A tri-target in silico analysis of Testolift: a nutraceutical formulation targeting aromatase, myostatin, and prolyl hydroxylase-2 in testosterone regulation and muscle performance.Scientific reports · 2026Article
- Natural Molecules for Brain Health and Resilience.International journal of molecular sciences · 2026Review
- Neuroimmune Regulation of Microvascular Inflammation: The Heart-Brain Axis, Mast Cells, and the Protective Role of Flavonoids-A Comprehensive Review.Biomedicines · 2026Review
- Dietary polyphenols and hepatocellular carcinoma: protective mechanisms, challenges, and future directions.Discover oncology · 2026Review
- Identifying Key Metabolites in South African Medicinal Plants Using Dual Electrospray Ionization Metabolomics.Plants (Basel, Switzerland) · 2026Article
- From Interaction to Intervention: Intentional CYP Inhibition as a Scalable Strategy to Expand Access to High-Cost Therapies.European journal of drug metabolism and pharmacokinetics · 2026Review
- Key Dietary Flavonoids: Insights into Their Structural Characteristics, Antioxidant and Anti-Inflammatory Activities, and Potential as Neuroprotective Agents.Molecules (Basel, Switzerland) · 2026Review
- Decoding the Bioactivity of Prunus armeniaca L. Essential Oil: Cheminformatics-Supported Exploration of Its Antioxidant and Antibacterial Potential.Chemistry & biodiversity · 2026Article
- Article
- Nanotechnology-Enhanced Delivery and Bioactivity of Dietary Flavonoids: Overcoming Bioavailability Barriers for Targeted Antimicrobial and Antiviral Therapies-A Comprehensive Review.International journal of nanomedicine · 2026Review
- An Evaluation of the Inhibitory Effect of Apatinib on Ilaprazole Metabolism: in vitro, in vivo and in silico Study.Drug design, development and therapy · 2026Article
- The Emerging Role of Senolysis in Atherosclerosis.Medicina (Kaunas, Lithuania) · 2025Review
- Dietary Phytochemicals in Cardiovascular Disease Prevention and Management: A Comprehensive Review.Food science & nutrition · 2025Review
- Antimicrobial activity of new glycoside derivatives of chloroflavones obtained by fungal biotransformation.Scientific reports · 2025Article
- Discovery of Dietary Plant Flavonols as Novel Potent Inhibitors Targeting DYRK1A Kinase.Biomolecules · 2025Article
- The Beneficial Use ofAnimals : an open access journal from MDPI · 2025Review
- Clinical Insights into Non-Alcoholic Fatty Liver Disease and the Therapeutic Potential of Flavonoids: An Update.Nutrients · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoids, a diverse group of polyphenolic compounds found abundantly in fruits, vegetables, and beverages like tea and wine, offer a plethora of health benefits. However, they have a potential interaction with drug metabolism, particularly through the inhibition of the cytochrome P450 3A4 enzyme, the most versatile and abundant enzyme in the liver. CYP3A4 is responsible for metabolizing approximately 50% of clinically prescribed drugs across diverse therapeutic classes, so these interactions have raised concerns about potential adverse effects. This review delves into the scientific evidence surrounding flavonoid-mediated CYP3A4 inhibition, exploring the inhibitory potential of investigated flavonoids and future implications. Kusehnol I, chrysin, leachianone A, and sophoraflavone G showed the largest inhibitory potentials and lowest
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.